Known targets — ChEMBL curated mechanism
BRAFFLT1FLT3FLT4KDRKITPDGFRBRAF1RET
The experimentally established mechanism targets of Cm-4307. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 known ✓ | P04049 | 12/20 | 0.88 |
| ▸ | KDR known ✓ | P35968 | 5/20 | 0.88 |
| ▸ | BRAF known ✓ | P15056 | 4/20 | 0.88 |
| ▸ | RET known ✓ | P07949 | 3/20 | 0.88 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.88 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 0.88 |
| ▸ | FLT1 known ✓ | P17948 | 2/20 | 0.88 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 0.88 |
| ▸ | FLT3 known ✓ | P36888 | 2/20 | 0.88 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.88 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.88 |
| ▸ | ABL1 | P00519 | 2/20 | 0.88 |
| ▸ | HTR1A | P08908 | 2/20 | 0.88 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.88 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.88 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.88 |
| ▸ | MAOA | P21397 | 2/20 | 0.88 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.88 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.88 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cm-4307 SCHEMBL30172564 | 1.00 | RAF1 (0.88) | RAF1KDRBRAFRETRIPK2 | |
| Cm-4307 SCHEMBL14480690 | 1.00 | RAF1 (0.88) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL14481281 | 0.95 | RAF1 (0.89) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL14481164 | 0.94 | RAF1 (0.88) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL14550501 | 0.94 | RAF1 (0.77) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL8218 | 0.93 | RAF1 (1.00) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL29349634 | 0.93 | RAF1 (1.00) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL14739751 | 0.93 | RAF1 (1.00) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL1533976 | 0.93 | RAF1 (0.98) | RAF1KDRBRAFRETRIPK2 | |
| Sorafenib SCHEMBL1533982 | 0.93 | RAF1 (0.98) | RAF1KDRBRAFRETRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630624-B2 | Anti-IL-27 antibodies and uses thereof | Surface Oncology, LLC (US) | 2026-05-19 | — | — | US | claimed |
| EP-4729510-A1 | INDOLE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Suzhou Merna Therapeutics Co. Ltd (CN) | 2026-04-22 | — | — | EP | claimed |
| US-20260021149-A1 | METHOD FOR TREATMENT OF TUMOR BY USING RECOMBINANT ONCOLYTIC VIRUS IN COMBINATION WITH SMALL-MOLECULE ANTICANCER DRUG | JOINT BIOSCIENCES SH LTD (CN) | 2026-01-22 | — | — | US | claimed |
| EP-4663205-A1 | POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF | Shanghai Best-Link Bioscience, LLC (CN) | 2025-12-17 | — | — | EP | claimed |
| US-12496342-B2 | Anti-CCR8 antibodies and uses thereof | VACCINEX, INC. (US) | 2025-12-16 | — | — | US | claimed |
| US-20250339399-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | BEIJING CREATRON INSTITUTE OF PHARMACEUTICAL RES CO LTD (CN) | 2025-11-06 | — | — | US | claimed |
| WO-2025226603-A1 | METHODS FOR TREATING CANCER USING ANTI-CCR8 ANTIBODIES | Surface Oncology, LLC (US) | 2025-10-30 | — | — | WO | claimed |
| EP-4612497-A2 | METHODS OF TREATING A TUMOR | Surface Oncology, LLC (US) | 2025-09-10 | — | — | EP | claimed |
| US-20250255977-A1 | EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | SHANGHAI BEST-LINK BIOSCIENCE, LLC (CN) | 2025-08-14 | — | — | US | claimed |
| WO-2025026214-A1 | TREATMENT OF P53 GENE MUTATION OR DEFECT NEGATIVE CANCER AND TUMOR PATIENTS | 深圳艾欣达伟医药科技有限公司 | 2025-02-06 | — | — | WO | claimed |
| WO-2023051685-A1 | METHOD FOR AMPLIFYING ERYTHROID PROGENITORS OR ERYTHROBLASTS, AND APPLICATION THEREOF | 北京大学 | 2023-04-06 | — | — | WO | claimed |
| US-20230042258-A1 | ANTI-IL-27 ANTIBODIES AND USES THEREOF | Surface Oncology, Inc. (US) | 2023-02-09 | — | — | US | claimed |
| CN-115501231-A | Combined pharmaceutical composition for preventing and/or treating liver cancer and application thereof | 安徽省立医院(中国科学技术大学附属第一医院) | 2022-12-23 | — | — | CN | claimed |
| EP-4087607-A1 | ANTI-CCR8 ANTIBODIES AND USES THEREOF | Vaccinex, Inc. (US) | 2022-11-16 | — | — | EP | claimed |
| WO-2022236134-A1 | ANTI-IL-27 ANTIBODIES AND USES THEREOF | Surface Oncology, Inc. (US) | 2022-11-10 | — | — | WO | claimed |
| CN-115068620-A | Pharmaceutical composition capable of reducing generation of arylamine impurities | 天津睿创康泰生物技术有限公司 | 2022-09-20 | — | — | CN | claimed |
| WO-2022165069-A1 | METHODS AND SYSTEMS FOR CHARACTERIZING AND TREATING COMBINED HEPATOCELLULAR CHOLANGIOCARCINOMA | FOUNDATION MEDICINE, INC. (US) | 2022-08-04 | — | — | WO | claimed |
| EP-4034559-A1 | ANTI-IL-27 ANTIBODIES AND USES THEREOF | Surface Oncology, Inc. (US) | 2022-08-03 | — | — | EP | claimed |
| CN-114796503-A | Application of KDM6A inhibitor and tyrosine kinase inhibitor in combination in preparation of anti-tumor drugs | 安徽省立医院(中国科学技术大学附属第一医院) | 2022-07-29 | — | — | CN | claimed |
| US-20220228224-A1 | METHOD FOR DETERMINING WHETHER BIOLOGICAL SAMPLE HASORIGINATED FROM LIVER CANCER TISSUE | LEPIDYNE CO., LTD. (KR) | 2022-07-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339399-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | S100A8, TP53, AQP1 | RAF1 2594/4885KDR 4187/4885BRAF 776/4885 |
| US-20250255977-A1 | EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | SLC7A1, KARS1, LNPEP | RAF1 3943/4885KDR 754/4885BRAF 4180/4885 |
| US-12630624-B2 | Anti-IL-27 antibodies and uses thereof | IL23R, IL36G, IL2 | RAF1 2658/4885KDR 419/4885BRAF 1880/4885 |
| US-20260021149-A1 | METHOD FOR TREATMENT OF TUMOR BY USING RECOMBINANT ONCOLYTIC VIRUS IN COMBINATION WITH SMALL-MOLECULE ANTICANCER DRUG | ERBB2, BTK, ERBB3 | RAF1 171/4885KDR 11/4885BRAF 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.